Patents Assigned to MyMD Pharmaceuticals, Inc.
-
Patent number: 11629355Abstract: Synthetic cannabinoid compounds for treatment of epilepsy, substance addiction, and Alzheimer's disease by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.Type: GrantFiled: July 22, 2021Date of Patent: April 18, 2023Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 10918633Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.Type: GrantFiled: February 17, 2020Date of Patent: February 16, 2021Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 10835523Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).Type: GrantFiled: February 10, 2020Date of Patent: November 17, 2020Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 10806728Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).Type: GrantFiled: November 4, 2019Date of Patent: October 20, 2020Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 10786493Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).Type: GrantFiled: February 14, 2020Date of Patent: September 29, 2020Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 10722506Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).Type: GrantFiled: December 3, 2019Date of Patent: July 28, 2020Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 10588899Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).Type: GrantFiled: March 31, 2016Date of Patent: March 17, 2020Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 10517856Abstract: In one aspect, a method of altering programmed cell death includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In other aspects, isomyosmine is administered to treat a wound, hemochromatosis, traumatic brain injury, or disorders associated with chronic oxidative stress. In other aspects, isomyosmine is administered to increase blood oxygen saturation levels.Type: GrantFiled: September 29, 2017Date of Patent: December 31, 2019Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 10471052Abstract: A pharmaceutical composition containing isomyosmine or a pharmaceutically acceptable salt thereof is administered to an individual in need thereof for treating a substance addiction, inclusive of addiction to heroin (diacetylmorphine), cocaine, opioids, methadone, d-methamphetamine, barbiturates, alcohol, benzodiazepines, amphetamines, or buprenorphine. The isomyosmine, along with optional additional therapeutic agent(s), may be administered in a capsule, tablet, or lozenge.Type: GrantFiled: January 19, 2018Date of Patent: November 12, 2019Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 10213438Abstract: Alkaloid compounds described herein are useful for treating disorders associated with monoamine oxidase (MAO) activity, such as depression, pain, smoking cessation, and substance addictions, and/or for treating disorders associated with chronic or low-level inflammation. In some examples, compounds are effective for treating cancers, autoimmune disorders, and other disorders associated with inducible nitric oxide synthase (iNOS).Type: GrantFiled: November 16, 2015Date of Patent: February 26, 2019Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Publication number: 20180042909Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).Type: ApplicationFiled: March 31, 2016Publication date: February 15, 2018Applicant: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams
-
Patent number: 9884055Abstract: A pharmaceutical composition containing isomyosmine or a pharmaceutically acceptable salt thereof is administered to an individual in need thereof for treating a substance addiction, inclusive of affecting smoking substitution, eliminating cravings for tobacco and nicotine, or transitioning individuals away from smoking or the use of other tobacco products. In some examples, the therapeutic agent(s) are administered in a capsule, tablet, or lozenge. In other examples, the therapeutic agent(s) are administered via a chewing gum, inhalation spray, e-cigarette, nasal spray, or transdermal patch.Type: GrantFiled: August 7, 2017Date of Patent: February 6, 2018Assignee: MyMD Pharmaceuticals, Inc.Inventor: Jonnie R. Williams